These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25387210)

  • 1. Reversal agents in development for the new oral anticoagulants.
    Costin J; Ansell J; Laulicht B; Bakhru S; Steiner S
    Postgrad Med; 2014 Nov; 126(7):19-24. PubMed ID: 25387210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
    Ruff CT; Giugliano RP; Antman EM
    Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
    Levy JH
    Am J Med; 2016 Nov; 129(11S):S47-S53. PubMed ID: 27569675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal agents for use with direct and indirect anticoagulants.
    Smythe MA; Trujillo T; Fanikos J
    Am J Health Syst Pharm; 2016 May; 73(10 Suppl 2):S27-48. PubMed ID: 27147456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
    Huisman MV; Fanikos J
    Am J Med; 2016 Nov; 129(11S):S89-S96. PubMed ID: 27569673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidotes for reversal of direct oral anticoagulants.
    Dobesh PP; Bhatt SH; Trujillo TC; Glaubius K
    Pharmacol Ther; 2019 Dec; 204():107405. PubMed ID: 31521696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
    Hussain SS; Tyroch AH; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):76-81. PubMed ID: 27215215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab.
    Hu TY; Vaidya VR; Asirvatham SJ
    Vasc Health Risk Manag; 2016; 12():35-44. PubMed ID: 26937198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options.
    Ansell JE
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):163-70. PubMed ID: 26872887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal agents for non-vitamin K antagonist oral anticoagulants.
    Levy JH; Douketis J; Weitz JI
    Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring and reversal of direct oral anticoagulants.
    Cuker A; Siegal D
    Hematology Am Soc Hematol Educ Program; 2015; 2015():117-24. PubMed ID: 26637710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.
    Ansell JE
    J Thromb Thrombolysis; 2016 Feb; 41(2):248-52. PubMed ID: 26449414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
    Huisman MV; Fanikos J
    Am J Emerg Med; 2016 Nov; 34(11S):46-51. PubMed ID: 27697438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
    Kaatz S; Mahan CE; Nakhle A; Gunasekaran K; Ali M; Lavender R; Paje DG
    Curr Cardiol Rep; 2017 Oct; 19(12):124. PubMed ID: 29064044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [State of the art: Direct oral anticoagulants and transfusion].
    Martin AC; Godier A; Smadja DM; Mauge L; Fischer AM
    Transfus Clin Biol; 2017 Sep; 24(3):154-159. PubMed ID: 28673500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician.
    Lohrmann GM; Atwal D; Augoustides JG; Askar W; Patel PA; Ghadimi K; Makar G; Gutsche JT; Shamoun FE; Ramakrishna H
    J Cardiothorac Vasc Anesth; 2016 Jun; 30(3):823-30. PubMed ID: 27080265
    [No Abstract]   [Full Text] [Related]  

  • 19. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
    Kaide CG; Gulseth MP
    J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of bleeding in patients receiving non-vitamin K antagonists.
    Balla S; Koerber S; Flaker G
    Postgrad Med J; 2017 Apr; 93(1098):221-225. PubMed ID: 27986971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.